Professor SHAW Pang Chui


(Office): Rm 180, Science Centre South Block
(Lab): Rm 195, Science Centre South Block

People PCS 2 


(Office): (852) 3943 1363 , 39436803
(Lab): (852) 3943 8027

Fax (852) 2603 7246
Email This email address is being protected from spambots. You need JavaScript enabled to view it.



1987 Ph.D. Imperial College, University of London
1983 M.Phil.. The Chinese University of Hong Kong
1981 B.Sc. The Chinese University of Hong Kong


  • Professor, School of Life Sciences
  • Director, Biochemistry Programme
  • Director, LDS YYC R & D Centre for Chinese Medicine
  • Deputy Director, Institute of Chinese Medicine
  • Master, Postgraduate Halls
  • Member, CUHK Council

Research Interests

  • Structure-function studies of proteins
  • Authentication and quality control of Chinese Medicinal material 

Representative Publications

  1. Lo, Y.T. and Shaw, P.C. (2019) Application of next-generation sequencing for the identification of herbal products. Biotechnol Adv. 37(8): 107450.
  1. Ho, S.T., Jin, R., Cheung, D.H., Huang, J.J. and Shaw, P.C. (2019) The PinX1/MPM interaction associates with hTERT in early-S phase and facilitates telomerase activation. Cell Biosci. 9: 47.
  1. Tang, Y.S., Lo, C.Y., Mok, C.K., Chan, P.K. and Shaw, P.C. (2019) The extended C-terminal region of influenza C virus nucleoprotein is important for nuclear import and ribonucleoprotein activity. Virol. 93(9).
  1. Loo, J.F., But, G.W., Kwok, H.C., Lau, P.M., Kong, S.K., Ho, H.P. and, Shaw, P.C. (2019) A rapid sample-to-answer analytical detection of genetically modified papaya using loop-mediated isothermal amplification assay on lab-on-a-disc for field use. Food Chem. 274: 822-830.
  1. Wong, T.H., But, G.W., Wu, H.Y., Tsang, S.S., Lau, D.T. and Shaw, P.C. (2018) Medicinal Materials DNA Barcode Database (MMDBD) version 1.5-one-stop solution for storage, BLAST, alignment and primer design. Database (Oxford). doi: 10.1093/database/bay112.
  1. Shi, W.W., Wong, K.B. and Shaw, P.C. (2018) Structural and Functional Investigation and Pharmacological mechanism of trichosanthin, a Type 1 ribosome-inactivating protein. Toxins (Basel). 10(8)
  1. Lo, Y.T., Yik, M.H., Shaw, P.C. (2018) Effective authentication of Placenta Hominis. Chin. Med. 13: 12.
  1. Lo, C.Y., Tang, Y.S. and Shaw, P.C. (2018) Structure and Function of Influenza Virus Ribonucleoprotein. Biochem. 88: 95-128.
  1. Zhang, T, Xiao, M., Wong, C.K., Mok, K.P.C., Zhao, X., Ti, H. and Shaw P.C. (2018) Shen Jiang San, a traditional multi-herb formulation, exerts anti-influenza effects in vitro and in vivo via neuraminidase inhibition and immune regulation. BMC Compl. Alter. Med. 18(1): 105.
  1. Shou, J.W., Zhang, R.R., Wu, H.Y., Xia X., Nie, H., Jiang, R.W. and Shaw, P.C. (2018) Isolation of novel bioflavonoids from Cardiocrinium giganteum var. yuannanense seeds and characterization of their antitussive activities. Ethnopharmacol.  222:171-176.
  1. Lo, C.Y., Li, O.T., Tang, W.P., Hu, C., Wang, G.X., Ngo, J.C., Wan, D.C., Poon, L.L. and Shaw, P.C. (2018) Identification of influenza polymerase inhibitors targeting C-terminal domain of PA through surface plasmon resonance screening. Rep. 8(1): 2280.
  1. Hsia, H.P., Yang, Y.H., Szeto, W.C., Nilsson, B.E., Lo, C.Y., Ng, A.K., Fodor, E. and Shaw, P.C. (2018) Amino acid substitutions affecting aspartic acid 605 and valine 606 decrease the interaction strength between the influenza virus RNA polymerase PB2 '627' domain and the viral nucleoprotein. PLoS One. 13(1): e0191226.
  1. Lo, Y.T. and Shaw, P.C. (2018) DNA barcoding in concentrated Chinese medicine granules using adaptor ligation-mediated polymerase chain reaction. J. Pharm. Biomed. Anal. 149: 512-516.
  1. Lo, Y.T. and Shaw, P.C. (2018) DNA-based techniques for authentication of processed food and food supplements. Food Chem. 240: 767-774.
  1. Lo, Y.T. and Shaw, P.C. (2017) Quantification of concentrated Chinese medicine granules by quantitative polymerase chain reaction. J. Pharm. Biomed. Anal. 145: 661-665.
  1. Liu, M., Lo, C.Y., Wang, G., Chow, H.F., Ngo, J.C, Wan, D.C., Poon, L.L. and Shaw, P.C. (2017) Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening. Antiviral Res. 144:186-195.
  1. Cheung, D.H.C., Ho, S.T., Lau, K.F., Jin, R., Wang, Y.N., Kung, H.F., Huang, J.J. and Shaw P.C. (2017) Nucleophosmin interacts with Pin2/Terf-1interacting telomerase inhibitor 1 (PinX1) and attenuates the PinX1 inhibition on telomerase activity. Sci Rep.  7: 43650.
  1. Au, K.Y., Shi, W.W., Qian, S., Zuo, Z. and Shaw, P.C. (2016) Improvement of the pharmacological properties of maize RIP by cysteine-specific PEGylation. Toxins (Basel), 8(10): 298.
  1. Shi, W.W., Tan, Y.S., Sze, S.Y., Zhu, Z.N., Wong, K.B. and Shaw, P.C. (2016) Crystal structure of ribosome-inactivating protein ricin A chain in complex with the C-terminal domain of the ribosomal stalk protein. Toxins (Basel), 8(10): 296.
  1. Jiang, J.J., Lo, Y.T., Chen, W.T. and Shaw, P.C. (2016) DNA authentication of animal-derived concentrated Chinese medicine granules. J. Pharm. Biomed. Anal. 129: 398-404.
  1. Ma, J.Y., Wong, K.L., Xu, Zy., Au, K.Y., Lee, N.L., Su, W.W., Li, P.B. and Shaw, P.C. (2016) N16, a nacreous protein, inhibits osteoclast differentiation and enhances osteogenesis. J. Nat. Prod. 79: 204-212.


  1. 曹暉、邵鵬柱、畢培曦主編(2016) 中藥分子鑒定 - 技術與應用。694頁。人民衛生出版社。
  1. 邵鵬柱、曹暉主編 (2004)中藥分子鑒定。329頁。復旦大學出版社。
  1. Shaw, P.C., Wang, J. and But, P.P.H. (ed.) (2002) Authentication of Chinese Medicinal Materials by DNA Technology. World Scientific Publishing Co. Ltd. Singapore. (The first international reference in this field of study)


  • 邵鵬柱, 鄭永唐, 黃錦波, 羅嘉懿, 王睿睿, 麥雅絲.2013. 修飾的玉米核糖體失活蛋白前體及其應用和蛋白純化方法. 中國專利CN102234638.
  • 邵鵬柱,畢培曦,徐宏喜,陳耀文,黃家樂. 2012. 用於鑒定有毒中藥材馬錢子品種的多核苷酸序列及其使用方法.中國專利CN10124537.
  • But, P.P.H., Xu, Y.T., Shaw, P.C., Jiang, R.W. and Hon, P.M. (2011) Method of making antitussive medicine and relieving cough. US Patent No. 7,867,998.
  • Shaw, P.C., Wang, J., But, P.P.H., Lau, T.W. (2004) The DNA sequences of medicinal Dendrobium and the application of these sequences for species identification and authentication. Chinese Patent ZL 01 1 02434.8.
  • Wang, J., Shaw, P.C., But, P.P.H., Ngai, K.F.N. (2003) Application of RFLP of DNA for the authentication of Chinese medicinal material. Chinese patent 98100001.0.
  • Shaw, P.C., Wang, J., But, P.P.H., Ha, W.Y., Yau, F.C.F. (2004) Sequence characterized amplified region (SCAR) test for the authentication of traditional Chinese medicinal materials. US Patent No. 6,803,215.
  • Wang, J., Shaw, P.C., But, P.P.H., Ngai, K.F.N. (2001) Polymerase chain reaction-restriction fragment length polymorphism test for the authentication of herbal Chinese medicines. U.S. Patent No. 6,309,840.

Research Grants

  1. Evaluation of anti-influenza properties of antrafenine and its analogs (Health and Medical Research Fund, 2019-22, HK$1,499,440)
  2. Molecular authentication of endangered timber samples – protocol development and evaluation on the scope of application (Environment and Conservation Fund, 2019-21, HK$1,290,562)
  3. Screening nickase enzyme candidates for the NGS technology designed by Genvida (Contract Research from Genvida (HK) Co. Ltd, 2019, $375,000)
  4. Isolation and characterization of unique RNA-N glycosidases from mushroom (Research Grants Council, 2018-20, HK$1,229,089)
  5. Development of rapid screening protocol to identify shark fins from endangered species (Environment and Conservation Fund, 2016-18, HK$986,696)
  6. Investigation of the antitussive effects of a folk medicine, cardiocrinum seeds. (Health and Medical Research Fund, 2015-17, $995,128)
  7. Study on the interaction of influenza A virus nucleoprotein and polymerase PB2 N-terminal region (Research Grants Council, 2015-17, $624,538)
  8. Establishment of new paradigm with feasible models in teaching and learning science for problem solving and future development (University Grants Committee, 2014-17, HK$10,000,000, as Co-PI)
  9. Structure-based drug design of anti-influenza compounds targeting influenza polymerase (Health and Medical Research Fund, 2014-16, $998,750)
  10. Preclinical Safety Evaluation and Mechanism Study of Nacre Protein N16:A New First-class Medicine for the Treatment of Osteoporosis (Innovation Technology Commission Fund, 2013-15, $689,955), with additional support of HK$406,993.54 for two additional interns
  11. Interaction study of PinX1 and nucleophosmin and the effect of inhibiting this interaction on tumor growth (Research Grants Council-National Natural Science Foundation of China Joint Research Scheme, 2013-2016, $1,016,658 + 15% on-cost)

Professional Activities

  • Editorial Board, Protein Engineering, Design and Selection
  • Co-Editor, Biodesign (Korea)
  • Editorial Board, Toxins (Basel)